MedTrace Logo

Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS)

NCT00677768 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 475

Last updated 2016-06-03

No results posted yet for this study

Summary

The purpose of this study is to collect 650 blood and 300 cerebrospinal fluid (CSF) samples from people with amyotrophic lateral sclerosis (ALS), pure lower or upper motor neuron diseases, as well as other neurodegenerative diseases and from people with no neurological disorder. Through comparison of these samples, the researchers hope to learn more about the underlying cause of ALS, as well as find unique biological markers, which could be used to diagnose ALS and monitor disease progression.

Additionally, up to 600 blood samples will be collected for a sub-study for DNA analysis. Studying components of the blood, such as DNA, may help us understand what happens when genes function abnormally and how it might be related to disease.

Conditions

Interventions

OTHER

No intervention

Sample collection

Sponsors & Collaborators

  • ALS Association

    collaborator OTHER

  • ALS Therapy Alliance

    collaborator OTHER

  • National Institutes of Health (NIH)

    collaborator NIH

  • National Institute of Neurological Disorders and Stroke (NINDS)

    collaborator NIH

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • James D. Berry, MD, MPH · Massachusetts General Hospital

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2015-11-30
Completion
2015-11-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00677768 on ClinicalTrials.gov